411
Participants
Start Date
October 11, 2021
Primary Completion Date
September 10, 2024
Study Completion Date
September 10, 2024
Insulin degludec
Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
Fast-acting insulin aspart
Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
HUB - Hôpital Erasme, Brussels
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Brussels
Bispebjerg Hospital, IC-Forskning, Copenhagen
UZA - UZ Antwerpen - Department of Endocrinology, Edegem
Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden
UZ Leuven - Endocrinology, Leuven
Centre Hospitalier Universitaire de Liège, Liège
Centre Hospitalier Universitaire de Caen Normandie- Cote de Nacre-1, Caen
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-2, Toulouse
Centre Hospitalier Universitaire de Montpellier-Hopital Lapeyronie, Montpellier
Frölunda Specialistsjukhus, Västra Frölunda
Chru de Nancy - Hopital Brabois, Vandœuvre-lès-Nancy
hôpital Saint Joseph Saint Luc, Lyon
Hospices Civils de Lyon-Hopital Lyon Sud-2, Pierre-Bénite
Ap-Hp-Hopital Bichat-Claude Bernard-1, Paris
Centre Hospitalier Sud Francilien, Corbeil-Essonnes
Diabetesmottagningen, Medicinkliniken, Södra Älvsborgs Sjukhus, Borås
Diabetesmottagningen, Södra Älvsborgs Sjukhus, Borås
Endokrinologiska kliniken, Malmö, Malmo
Medicinmottagning1 Universitetssjukhuset Örebro, Örebro
Centrum for Diabetes, Academical Specialist Centrum, Stockholm
Medicinkliniken Sundsv, Sundsvall
Akademiska sjukhuset Uppsala, Uppsala
Lead Sponsor
Novo Nordisk A/S
INDUSTRY